000			03743nam a22004215i 4500
999			_c11463 _d11463
001			11463
003			DE-He213
005			20210713040332.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180802s2018 gw | s |||| 0|eng d
020			_a9783319785592
024	7		_a10.1007/978-3-319-78559-2 _2doi
040			_aES-MaUEC _bspa _dES-VaUE
050		4	_aRC280 _b.T74 2018 EB
245	1	0	_aTreating Urothelial Bladder Cancer _cedited by Francesco Soria, Paolo Gontero.
264		1	_aCham, Switzerland _bSpringer _c2018
300			_a1 recurso en línea (VIII, 133 páginas 25 ilustraciones, 18 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aMedicine (Springer-11650)
505	0		_aPreface -- Part I: Bladder cancer diagnosis -- Imaging and bladder cancer: can we do better? -- Optical improvements in bladder cancer diagnosis: seeing better for a better management -- Enhancing the quality of transurethral resection: the importance of a complete TURB and the en-bloc resection -- Active surveillance for low risk non-muscle invasive bladder cancer -- Part II: Non-muscle invasive bladder cancer -- How good we are to predict the outcomes of non-muscle invasive bladder cancer? -- Adjuvant treatment: old and new immunotherapy in non-muscle invasive bladder cancer -- The role of new experimental conservative therapies for high risk non-muscle invasive bladder cancer. Could we trust them? -- Part III: Muscle invasive bladder cancer -- Is there still a role for radical cystectomy? -- Minimally invasive radical cystectomy and its role in the treatment of bladder cancer patients. Myth or reality? -- Neoadjuvant vs adjuvant chemotherapy: which is right? -- Radiotherapy for the treatment of muscle invasive bladder cancer -- Immunotherapy and new combinations -- Part IV: A view on the future -- The role of urologist -- The role of pathologist -- The role of medical oncologist -- The role of radiotherapist.
520	3		_aThis book aims to bring together the current research and discussions surrounding bladder cancer management. New technologies and therapeutic agents have become increasingly effective at treating urothelial bladder cancer and have created a range of opportunities to change the ways in which the disease is treated. Chapters cover the changes in adjuvant treatment, confocal laser endomicroscopy, and the roles of oncologists, pathologists, and radiotherapists in managing bladder cancer. Treating Urothelial Bladder Cancer is particularly relevant to urologists, oncologists, and radiotherapists, but is also applicable to practitioners, geriatricians, and public health managers due to its multidisciplinary approach to bladder cancer management.
988			_aEBSPRINGER_2018
650		7	_aVejiga _xCáncer _9667082 _2embne
650		7	_aUrología _2embne _9138565
650		7	_aOncología _9139207 _2embne
700	1		_aSoria, Francesco _eeditor literario _0http://viaf.org/viaf/74200014
700	1		_aGontero, Paolo _eeditor literario _0http://id.loc.gov/authorities/names/n2013185601 _0http://viaf.org/viaf/305199143
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319785585
776	0	8	_iEdición impresa: _z9783319785608
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-78559-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0